Executive Summary
The business has attractive characteristics: consumable products embedded in customer processes, technical service, global Vesuvius R&D access, low debt and strong cash generation. The Morganite transaction adds crucibles, higher-margin non-ferrous exposure and cross-selling. The Mehsana facility can add further scale after expected completion by 31 December 2026.
Investment stance: high quality, high expectations. At about 44.8 times trailing earnings, execution of integration synergies and sustained 23–25% operating margins are necessary merely to support the current valuation.
H1 And Q2 CY26 Snapshot
| Metric | Q1 CY26 | Q2 CY26 | H1 CY26 | Interpretation |
|---|---|---|---|---|
| Revenue | ₹201.9 Cr | ₹231.4 Cr | ₹433.3 Cr | Acquired crucible business changes comparability |
| Operating profit / OPM | ₹41 Cr / 20% | ₹53 Cr / 23% | — | Reported Screener operating measure |
| Adjusted EBITDA | ₹49.7 Cr / 24.6% | ₹58.3 Cr / 25.2% | ₹108.0 Cr / 24.9% | Deck excludes exceptional items |
| Adjusted PBT | ₹41.4 Cr | ₹50.1 Cr | ₹91.5 Cr | 21.1% H1 PBT margin |
Business Quality
Foseco sells consumables, equipment and application expertise that improve casting yield, cleanliness, surface finish and process control. Products span feeding systems, coatings, binders, filters, ferrous and non-ferrous metal treatment, and now crucibles. The value proposition is a small input cost relative to the customer’s cost of rejection and downtime.
Moat
- Vesuvius technology, six global R&D centres and local adaptation.
- On-site technical service creates customer stickiness.
- Broad coverage across the foundry process.
- Automotive, rail, power, mining, wind and engineering diversification.
Limits
- Demand remains linked to foundry and industrial cycles.
- Premium products face local and global competition.
- Related-party acquisitions require governance scrutiny.
- Merger accounting obscures organic comparison.
Acquisition-Led Transformation
| Transaction | Terms / Timing | Strategic Read-through |
|---|---|---|
| Morganite Crucible India | 75% acquired; 11,50,800 Foseco shares issued; minimal cash expenditure | Adds leader in crucibles, non-ferrous exposure, cross-selling and procurement/manufacturing synergies |
| Mehsana facility from Vesuvius India | ₹43.25 Cr cash; expected completion by 31 Dec 2026 | FY25 revenue base ₹58.1 Cr; adds crucibles, sleeves, inserts and ladle bowls |
Foseco Crucible’s H1 CY26 revenue was ₹88.3 crore, EBITDA margin 39.8% and PBT margin 33.4%. Those economics explain the consolidated margin lift, but investors should test whether they remain durable after purchase accounting, integration and competitive response.
Growth Drivers
- Cross-selling: crucibles into Foseco accounts and foundry consumables into Morganite accounts.
- Advanced castings: EVs, aluminium adoption and tighter tolerances increase technical demands.
- Industrial cycle: auto, infrastructure, railways, mining, wind and ductile-iron pipes support volume.
- Premiumisation: simulation-led solutions can reduce rejection, energy and total casting cost.
- Localisation: India-specific R&D and local manufacturing can shorten lead times.
Financial Quality
The cash-rich balance sheet is a major strength. However, the enlarged equity base and acquired goodwill/assets reduce direct comparability with legacy ROE. Future quality should be judged on cash conversion, consolidated ROCE and integration synergies.
Valuation
At ₹6,194.50, market capitalisation was about ₹4,669 crore and trailing P/E 44.8 times. The multiple is consistent with a premium niche franchise, but leaves little room for foundry-volume weakness or margin normalization.
| Case | CY26 EPS | Assigned P/E | Indicative value | Condition |
|---|---|---|---|---|
| Bear | ₹150 | 28x | ₹4,200 | Integration drag and 21–22% margin |
| Base | ₹175 | 35x | ₹6,125 | Stable 24–25% adjusted EBITDA margin |
| Bull | ₹190 | 40x | ₹7,600 | Fast synergy capture and resilient crucible margins |
Key Risks
Business
- Auto and industrial foundry cyclicality.
- Raw-material and currency volatility.
- Price pressure from expanding competitors.
- Customer resistance to premium solutions.
Transaction
- Morganite synergy and integration shortfall.
- Mehsana regulatory/sub-lease completion risk.
- Related-party transaction perception.
- High valuation and enlarged share count.
Projection If Management Walks The Talk
Assumptions: H1 momentum continues, Morganite synergies are retained, core Foseco grows at a healthy low-double-digit rate, and Mehsana closes at calendar year-end without material CY26 contribution. EPS uses approximately 0.814 crore shares.
| Period | Revenue | Expected OPM | Expected EBITDA margin | PAT | Expected EPS | Key variable |
|---|---|---|---|---|---|---|
| Q3 CY26 | ₹220–240 Cr | 22–24% | 24–25% | ₹33–38 Cr | ₹40.5–46.7 | Crucible margin and auto demand |
| Q4 CY26 | ₹225–250 Cr | 22–24% | 24–25% | ₹34–40 Cr | ₹41.8–49.1 | Integration and year-end mix |
| Q1 CY27 | ₹235–260 Cr | 22–24% | 24–25.5% | ₹36–42 Cr | ₹44.2–51.6 | Mehsana consolidation |
| Q2 CY27 | ₹250–275 Cr | 23–25% | 25–26% | ₹39–46 Cr | ₹47.9–56.5 | Cross-selling and utilisation |
| CY26 case | Revenue | Expected OPM | Expected EBITDA margin | PAT | Expected EPS |
|---|---|---|---|---|---|
| Conservative | ₹850–875 Cr | 21–22% | 22.5–23.5% | ₹122–130 Cr | ₹150–160 |
| Base | ₹880–915 Cr | 22–23.5% | 24–25% | ₹138–148 Cr | ₹170–182 |
| Optimistic | ₹920–950 Cr | 24–25% | 25.5–26.5% | ₹150–158 Cr | ₹184–194 |
Investor Watchlist
- Organic revenue growth separated from acquired revenue.
- Foseco Crucible EBITDA margin after full integration.
- Cross-selling evidence and procurement synergies.
- Mehsana completion by 31 December 2026.
- Consolidated cash, ROCE and working-capital days.
- Any disclosure of acquisition goodwill and amortisation.